这是一种改良的玻璃微纤维滤纸,无粘结剂,表面光滑,在更快的流速和高负载下,具有极好的颗粒物截留度,934-AH是*水质检测站每天测定总悬浮固体和总溶解性固体的标准过滤膜,它还可去除浑浊物和过滤培养基。zui近又称为国家标准方法中huang qu mei du su、赭曲霉毒素等样品过滤分离玻璃微纤维滤纸(1.5um 直径11cm),还可用于液闪计数、细胞培养和空气污染监测。
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent Solubility
In Vitro:;
H2O
Peptide Solubility and Storage Guidelines:
1.;;Calculate the length of the peptide.
2.;;Calculate the overall charge of the entire peptide according to the following table:
;
Contents
Assign value
Acidic amino acid
Asp (D), Glu (E), and the C-terminal -COOH.
-1
Basic amino acid
Arg (R), Lys (K), His (H), and the N-terminal -NH2
+1
Neutral amino acid
Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q)
0
3.;;Recommended solution:
Overall charge of peptide
Details
Negative (lt;0)
1.;;Try to dissolve the peptide in water first. 2.;;If water fails, add NH4OH (lt;50 μL). 3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0)
1.;;Try to dissolve the peptide in water first. 2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution. 3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0)
1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first. 2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献
[1]. M L Garcia, et al. Purification and characterization of three inhibitors of voltage-dependent K+ channels from Leiurus quinquestriatus var. hebraeus venom. Biochemistry. 1994 Jun 7;33(22):6834-9.
[2]. Raveendra Anangi, et al. Recombinant expression of margatoxin and agitoxin-2 in Pichia pastoris: an efficient method for production of KV1.3 channel blockers.
Plasmocin™ is used to cure cell lines infected by mycoplasma and related cell wall-less bacteria. Plasmocin™ can also be used as a routine addition in liquid media to prevent mycoplasma and more generally bacterial contamination in small and large animal cell cultures. More info on Mycoplasma eradication
Plasmocin™ is a well-established antimycoplasma reagent. It contains two bactericidal components strongly active against mycoplasmas that allow their elimination in only 2 weeks. The first component acts on the protein synthesis machinery while the second acts on the DNA replication. These two specific and separate targets are found only in mycoplasmas and many other bacteria and are compley absent in eukaryotic cells.
Warning: InvivoGen's anti-mycoplasma products are suitable for research purposes only, and not for human or animal care.
Specifications
Docs
Contents
Description
Details
Citations
– Active on both free mycoplasmas and intracellular forms – No resistance in liquid cultures of mycoplasmas – No apparent adverse effect on cellular metabolism – Active at low concentrations on a broad range of Gram positive and negative bacteria – Eliminates mycoplasma in as little as 2 weeks – Treat up to 25 cell lines in T75
MSDS Plasmocin™ prophylactic : 25 mg (10 x 1 ml) (ant-mpp) , 50 mg (2 x 1 ml) (ant-mpt)
Plasmocin™ is provided as a yellow solution at different concentrations:
– 25 mg/ml (Plasmocin™Treatment)
– 2.5 mg/ml (Plasmocin™ Prophylactic)
In contrast to other anti-mycoplasma compounds, Plasmocin™ is active on both free mycoplasmas and intracellular forms. This advantage is conferred by one component of Plasmocin™ which is actively transported into mammalian cells. It ensures that following treatment with Plasmocin™ a cell culture is not reinfected by mycoplasmas released from intracellular compartments of infected cells.
In all animal cell lines tested to date, even at five times the working concentration, no apparent adverse effect on cellular metabolism is observed.
No resistance in liquid cultures of mycoplasmas has ever been identified in repeated experiments attempting to measure the mutation rate. Therefore, development of resistant mycoplasma strains is virtually eliminated.
Plasmocin™ is also active at low concentrations on a broad range of Gram positive and Gram negative bacteria that are otherwise resistant to the mixture of streptomycin and penicillin, and exhibits no toxicity in eukaryotic cells.
Many cell lines infected by mycoplasmas have been successfully treated with Plasmocin™, including embryonic stem cells, hybridomas and retrovirus packaging cells.
Comparison of the most common anti-mycoplasma agents[1-3]
Product
Supplier
Treatment
Ease of use
Efficacy
Cytotoxicity
Resistance
BM-Cyclin
Roche
3 weeks
–
+++
+
+/-
Ciprobay
Bayer
12 to 20 days
+
++
+/-
+
MRA
ICN
1 to 2 weeks
+
++
+/-
+
Plasmocin
InvivoGen
2 weeks
+
+++
+/-
–
Antibiotics commonly used in cell culture are inactive on mycoplasma (e.g. penicillins and streptomycin). Three classes of antibiotics have been shown to kill mycoplasma at relatively low concentrations: tetracyclines, macrolides and quinolones. Tetracyclines and macrolides block the protein synthesis by interfering with ribosome translation, while quinolones inhibit the replication of bacterial DNA. Several antibiotics are commercially available for the removal of mycoplasma: BM-cyclin (Roche) contains a macrolide and a tetracycline, Ciprobay (Bayer, available only with a prescription) and MRA (ICN) are both quinolones. Plasmocin™ is the only antimycoplasma reagent that combines a macrolide and a quinolone. Unlike BM-Cyclin that requires the sequential and cyclic use of 2 antibiotics, Plasmocin™ is ready-to-use and can be added to the culture medium directly. Furthermore, the 2 antibiotics in Plasmocin™ act on separate targets blocking protein synthesis and DNA replication, whereas the 2 antibiotics in BM-Cyclin are both inhibitors of protein synthesis. Therefore, Plasmocin™ is more effective in removing mycoplasma and prevents the appearance of resistant strains. In contrast to other anti-mycoplasma compounds, Plasmocin™ is active on both free mycoplasma as well as intracellular forms. This advantage is conferred by one component of Plasmocin™ which is actively transported into mammalian cells. It ensures that following treatment with Plasmocin™ a cell culture is not reinfected by mycoplasma released from intracellular compartments of infected cells. To date, no consistent and permanent alterations that affect the eukaryotic cells during and after the treatment have been detected[1].
1. Uphoff CC, Drexler HG., 2005. Eradication of mycoplasma contaminations. Methods Mol Biol. 290:25-34. 2. Somasundaram C. et al., 1992. Use of ciprofloxacin and BM-Cyclin in mycoplasma decontamination.In Vitro Cell Dev Biol. 28A(11-12):708-10 3. Drexler HG. et al., 1994. Treatment of mycoplasma contamination in a large panel of cell cultures. In vitro Cell Dev Biol Anim. 30A(5):344-7
Recent articles using Plasmocin™
2012 – J Virol Methods., Epub ahead of print Mycoplasma removal: Simple curative methods for viral supernatants. Baronti C, Pastorino B, Charrel R, de Lamballerie X
2011 – Mol Pharmacol., 80(6):1066-75 Ca2+/calmodulin-dependent kinase (CaMK) signaling via CaMKI and AMP-activated protein kinase contributes to the regulation of WIPI-1 at the onset of autophagy. Pfisterer SG, Mauthe M, Codogno P, Proikas-Cezanne T
2011 – J Immunol., 186(12):6822-6829 Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80. Haile ST, Bosch JJ, Agu NI, Zeender AM, Somasundaram P, Srivastava MK, Britting S, Wolf JB, Ksander BR, Ostrand-Rosenberg S
2012 – J. Biol. Chem., 287: 8082 – 8091 Loss of lysosomal ion channel transient receptor potential channel mucolipin-1 (TRPML1) leads to cathepsin B-dependent apoptosis. Colletti GA, Miedel MT, Quinn J, Andharia N, Weisz OA, Kiselyov K
2012 – Immunity, 36(3):464-476 An NLRP7-containing inflammasome mediates recognition of microbial lipopeptides in human macrophages. Khare S, Dorfleutner A, Bryan NB, Yun C, Radian AD, de Almeida L, Rojanasakul Y, Stehlik C
ORDERING
Plasmocin™ prophylactic
Description
Removal agent to prevent mycoplasma contamination
Cat. Code
ant-mpp
Unit Size
25 mg (10 x 1 ml)
Price
Please contact our distributor
TDS
MSDS
Plasmocin™ treatment
Description
Removal agent to eliminate mycoplasmas
Cat. Code
ant-mpt
Unit Size
50 mg (2 x 1 ml)
Price
Please contact our distributor
TDS
MSDS
YOU MAY ALSO NEED
PlasmoTest™
Detection of mycoplasma contamination in cell culture kit
Normocin™
Antimicrobial agent for prevention against Mycoplasma, Bacteria and Fungi
Fungin™
Antimicrobial agent for prevention and elimination of Fungi
Plasmocin™ is used to cure cell lines infected by mycoplasma and related cell wall-less bacteria. Plasmocin™ can also be used as a routine addition in liquid media to prevent mycoplasma and more generally bacterial contamination in small and large animal cell cultures. More info on Mycoplasma eradication
Plasmocin™ is a well-established antimycoplasma reagent. It contains two bactericidal components strongly active against mycoplasmas that allow their elimination in only 2 weeks. The first component acts on the protein synthesis machinery while the second acts on the DNA replication. These two specific and separate targets are found only in mycoplasmas and many other bacteria and are compley absent in eukaryotic cells.
Warning: InvivoGen's anti-mycoplasma products are suitable for research purposes only, and not for human or animal care.
Specifications
Docs
Contents
Description
Details
Citations
– Active on both free mycoplasmas and intracellular forms – No resistance in liquid cultures of mycoplasmas – No apparent adverse effect on cellular metabolism – Active at low concentrations on a broad range of Gram positive and negative bacteria – Eliminates mycoplasma in as little as 2 weeks – Treat up to 25 cell lines in T75
MSDS Plasmocin™ prophylactic : 25 mg (10 x 1 ml) (ant-mpp) , 50 mg (2 x 1 ml) (ant-mpt)
Plasmocin™ is provided as a yellow solution at different concentrations:
– 25 mg/ml (Plasmocin™Treatment)
– 2.5 mg/ml (Plasmocin™ Prophylactic)
In contrast to other anti-mycoplasma compounds, Plasmocin™ is active on both free mycoplasmas and intracellular forms. This advantage is conferred by one component of Plasmocin™ which is actively transported into mammalian cells. It ensures that following treatment with Plasmocin™ a cell culture is not reinfected by mycoplasmas released from intracellular compartments of infected cells.
In all animal cell lines tested to date, even at five times the working concentration, no apparent adverse effect on cellular metabolism is observed.
No resistance in liquid cultures of mycoplasmas has ever been identified in repeated experiments attempting to measure the mutation rate. Therefore, development of resistant mycoplasma strains is virtually eliminated.
Plasmocin™ is also active at low concentrations on a broad range of Gram positive and Gram negative bacteria that are otherwise resistant to the mixture of streptomycin and penicillin, and exhibits no toxicity in eukaryotic cells.
Many cell lines infected by mycoplasmas have been successfully treated with Plasmocin™, including embryonic stem cells, hybridomas and retrovirus packaging cells.
Comparison of the most common anti-mycoplasma agents[1-3]
Product
Supplier
Treatment
Ease of use
Efficacy
Cytotoxicity
Resistance
BM-Cyclin
Roche
3 weeks
–
+++
+
+/-
Ciprobay
Bayer
12 to 20 days
+
++
+/-
+
MRA
ICN
1 to 2 weeks
+
++
+/-
+
Plasmocin
InvivoGen
2 weeks
+
+++
+/-
–
Antibiotics commonly used in cell culture are inactive on mycoplasma (e.g. penicillins and streptomycin). Three classes of antibiotics have been shown to kill mycoplasma at relatively low concentrations: tetracyclines, macrolides and quinolones. Tetracyclines and macrolides block the protein synthesis by interfering with ribosome translation, while quinolones inhibit the replication of bacterial DNA. Several antibiotics are commercially available for the removal of mycoplasma: BM-cyclin (Roche) contains a macrolide and a tetracycline, Ciprobay (Bayer, available only with a prescription) and MRA (ICN) are both quinolones. Plasmocin™ is the only antimycoplasma reagent that combines a macrolide and a quinolone. Unlike BM-Cyclin that requires the sequential and cyclic use of 2 antibiotics, Plasmocin™ is ready-to-use and can be added to the culture medium directly. Furthermore, the 2 antibiotics in Plasmocin™ act on separate targets blocking protein synthesis and DNA replication, whereas the 2 antibiotics in BM-Cyclin are both inhibitors of protein synthesis. Therefore, Plasmocin™ is more effective in removing mycoplasma and prevents the appearance of resistant strains. In contrast to other anti-mycoplasma compounds, Plasmocin™ is active on both free mycoplasma as well as intracellular forms. This advantage is conferred by one component of Plasmocin™ which is actively transported into mammalian cells. It ensures that following treatment with Plasmocin™ a cell culture is not reinfected by mycoplasma released from intracellular compartments of infected cells. To date, no consistent and permanent alterations that affect the eukaryotic cells during and after the treatment have been detected[1].
1. Uphoff CC, Drexler HG., 2005. Eradication of mycoplasma contaminations. Methods Mol Biol. 290:25-34. 2. Somasundaram C. et al., 1992. Use of ciprofloxacin and BM-Cyclin in mycoplasma decontamination.In Vitro Cell Dev Biol. 28A(11-12):708-10 3. Drexler HG. et al., 1994. Treatment of mycoplasma contamination in a large panel of cell cultures. In vitro Cell Dev Biol Anim. 30A(5):344-7
Recent articles using Plasmocin™
2012 – J Virol Methods., Epub ahead of print Mycoplasma removal: Simple curative methods for viral supernatants. Baronti C, Pastorino B, Charrel R, de Lamballerie X
2011 – Mol Pharmacol., 80(6):1066-75 Ca2+/calmodulin-dependent kinase (CaMK) signaling via CaMKI and AMP-activated protein kinase contributes to the regulation of WIPI-1 at the onset of autophagy. Pfisterer SG, Mauthe M, Codogno P, Proikas-Cezanne T
2011 – J Immunol., 186(12):6822-6829 Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80. Haile ST, Bosch JJ, Agu NI, Zeender AM, Somasundaram P, Srivastava MK, Britting S, Wolf JB, Ksander BR, Ostrand-Rosenberg S
2012 – J. Biol. Chem., 287: 8082 – 8091 Loss of lysosomal ion channel transient receptor potential channel mucolipin-1 (TRPML1) leads to cathepsin B-dependent apoptosis. Colletti GA, Miedel MT, Quinn J, Andharia N, Weisz OA, Kiselyov K
2012 – Immunity, 36(3):464-476 An NLRP7-containing inflammasome mediates recognition of microbial lipopeptides in human macrophages. Khare S, Dorfleutner A, Bryan NB, Yun C, Radian AD, de Almeida L, Rojanasakul Y, Stehlik C
ORDERING
Plasmocin™ prophylactic
Description
Removal agent to prevent mycoplasma contamination
Cat. Code
ant-mpp
Unit Size
25 mg (10 x 1 ml)
Price
Please contact our distributor
TDS
MSDS
Plasmocin™ treatment
Description
Removal agent to eliminate mycoplasmas
Cat. Code
ant-mpt
Unit Size
50 mg (2 x 1 ml)
Price
Please contact our distributor
TDS
MSDS
YOU MAY ALSO NEED
PlasmoTest™
Detection of mycoplasma contamination in cell culture kit
Normocin™
Antimicrobial agent for prevention against Mycoplasma, Bacteria and Fungi
Fungin™
Antimicrobial agent for prevention and elimination of Fungi
C3bot(154-182) is a C3 peptide enhances recovery from spinal cord injury by improving regenerative growth of descending fiber tracts. C3bot(154-182) represents a promising tool to foster axonal protection and/or repair, as well as functional recovery after traumatic CNS injury[1].
体外研究 (In Vitro)
C3bot(154-182) stimulates regenerative growth of raphespinal fibers and improves serotonergic input to lumbar α-motoneurons[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
分子量
3058.51
Formula
C137H221N37O40S
CAS 号
1246280-79-4
Sequence Shortening
VAKGSKAGYIDPISAFAGQLEMLLPRHST
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent Solubility
In Vitro:;
H2O
Peptide Solubility and Storage Guidelines:
1.;;Calculate the length of the peptide.
2.;;Calculate the overall charge of the entire peptide according to the following table:
;
Contents
Assign value
Acidic amino acid
Asp (D), Glu (E), and the C-terminal -COOH.
-1
Basic amino acid
Arg (R), Lys (K), His (H), and the N-terminal -NH2
+1
Neutral amino acid
Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q)
0
3.;;Recommended solution:
Overall charge of peptide
Details
Negative (lt;0)
1.;;Try to dissolve the peptide in water first. 2.;;If water fails, add NH4OH (lt;50 μL). 3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0)
1.;;Try to dissolve the peptide in water first. 2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution. 3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0)
1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first. 2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献
[1]. Francesco Boato, et al. C3 peptide enhances recovery from spinal cord injury by improved regenerative growth of descending fiber tracts. J Cell Sci. 2010 May 15;123(Pt 10):1652-62.